StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Aristotle

<< Previous

Bullboard Posts

Next >>

Post by 4real4everon Dec 16, 2020 6:50pm

311 Views

Post# 32124731

Aristotle

For novices and pumpers

Even though Aristotle launches in early 2021, the share price will never go above $1.50. And before Aristotle earns enough to raise the share price, if Aristotle earns anything, it will take years. Just looking at the money made with other szls products in the last few years. This company is a disgrace to investors, the cancer industry and the TSX.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market